Brazil signs technology transfer deals worth $1.5 billion
This article was originally published in Scrip
Pfizer, the Israeli firm Protalix and the Brazilian health ministry have signed a R$1.25 billion ($734 million) technology transfer deal that will see the state-owned pharmaceutical lab, Biomanguinhos, produce generic versions of Uplyso (taliglucerase alfa) for Gaucher's disease within five years.
You may also be interested in...
Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.